FY2025 EPS Estimates for Bruker Co. Decreased by Zacks Research (NASDAQ:BRKR)

Bruker Co. (NASDAQ:BRKR) – Analysts at Zacks Research dropped their FY2025 EPS estimates for Bruker in a report issued on Wednesday, September 18th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings per share of $3.07 for the year, down from their prior estimate of $3.09. The consensus estimate for Bruker’s current full-year earnings is $2.61 per share. Zacks Research also issued estimates for Bruker’s FY2026 earnings at $3.64 EPS.

Other equities research analysts also recently issued reports about the stock. Jefferies Financial Group assumed coverage on shares of Bruker in a research note on Monday, June 3rd. They issued a “buy” rating and a $85.00 target price for the company. Citigroup dropped their target price on Bruker from $95.00 to $80.00 and set a “buy” rating on the stock in a research note on Wednesday, July 10th. TD Cowen decreased their price target on Bruker from $74.00 to $72.00 and set a “hold” rating for the company in a research note on Wednesday, August 7th. The Goldman Sachs Group dropped their price target on Bruker from $72.00 to $60.00 and set a “sell” rating on the stock in a research note on Tuesday, July 9th. Finally, Wells Fargo & Company started coverage on shares of Bruker in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $78.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $81.40.

Bruker Stock Performance

Shares of Bruker stock opened at $68.26 on Friday. Bruker has a one year low of $53.79 and a one year high of $94.86. The company has a market capitalization of $9.92 billion, a PE ratio of 24.82, a P/E/G ratio of 2.31 and a beta of 1.18. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.75 and a current ratio of 1.65. The company has a 50-day simple moving average of $64.42 and a two-hundred day simple moving average of $73.07.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Tuesday, August 6th. The medical research company reported $0.52 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.52. The business had revenue of $800.70 million for the quarter, compared to the consensus estimate of $799.44 million. Bruker had a return on equity of 24.92% and a net margin of 11.29%. The business’s revenue was up 17.4% compared to the same quarter last year. During the same period last year, the business posted $0.50 EPS.

Hedge Funds Weigh In On Bruker

Several large investors have recently made changes to their positions in BRKR. Lifestyle Asset Management Inc. lifted its position in shares of Bruker by 1.3% in the first quarter. Lifestyle Asset Management Inc. now owns 12,534 shares of the medical research company’s stock valued at $1,177,000 after acquiring an additional 158 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in Bruker by 20.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 991 shares of the medical research company’s stock worth $63,000 after purchasing an additional 165 shares during the last quarter. Securian Asset Management Inc. grew its holdings in shares of Bruker by 2.3% during the second quarter. Securian Asset Management Inc. now owns 7,766 shares of the medical research company’s stock worth $496,000 after buying an additional 175 shares in the last quarter. Park Place Capital Corp raised its position in shares of Bruker by 19.4% in the first quarter. Park Place Capital Corp now owns 1,139 shares of the medical research company’s stock valued at $107,000 after buying an additional 185 shares during the last quarter. Finally, Assetmark Inc. lifted its stake in shares of Bruker by 24.7% in the fourth quarter. Assetmark Inc. now owns 1,005 shares of the medical research company’s stock worth $74,000 after buying an additional 199 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, September 16th. Investors of record on Monday, September 2nd were given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.29%. The ex-dividend date of this dividend was Friday, August 30th. Bruker’s dividend payout ratio is currently 7.27%.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.